Anti-TNF antibody treatment of Crohn's disease.

نویسنده

  • S J van Deventer
چکیده

Crohn’s disease and ulcerative colitis are the two idiopathic chronic inflammatory bowel diseases. Although these diseases may show substantial phenotypic overlap, it is widely accepted that these represent distinct pathogenic entities. The cause of neither ulcerative colitis nor Crohn’s disease is known, and genetic as well as environmental factors have been implicated. Previous reports implicating single microbial pathogens (Mycobacterium paratuberculosis, measles) in Crohn’s disease are controversial and have not been confirmed. On the other hand, evidence that antigen driven ill controlled activation of mucosal T lymphocytes is a major disease mechanism has accumulated in recent years, and this has led to novel therapeutic strategies. I here review the clinical results of anti-TNF antibody treatment against the background of current knowledge of the regulation of mucosal immune activation.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease

CONTEXT Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn's disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. Schwartz was an investigator of the PRECiSE (PEGylated Antibody Fragment Evaluation in Crohn's Dise...

متن کامل

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.

BACKGROUND In Crohn's disease, inflammation is presumably sustained by an increased production of proinflammatory cytokines, in particular tumour necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL 1 beta). TNF alpha can induce a host of cellular effector events resulting in perpetuation of the inflammatory process. In vivo studies with anti-TNF alpha antibody treatment have led to imp...

متن کامل

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.

INTRODUCTION Adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimuma...

متن کامل

Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.

The management of Crohn's disease and ulcerative colitis has become increasingly complex. With the current utilization of immunosuppressive therapies earlier in the disease course for patients presenting with moderate to severe disease, there is a great need for additional biologic agents targeting inflammatory mediators other than anti-tumor necrosis factor-α (anti-TNF) agents. Although anti-T...

متن کامل

Infliximab in ulcerative colitis

Infliximab, a monoclonal anti-TNF-alpha antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-alpha in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the...

متن کامل

Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.

BACKGROUND AND AIMS Intestinal barrier function in Crohn's disease patients and their first degree healthy relatives is impaired. The increased intestinal permeability may result in an enhanced mucosal immune response and thereby aggravate intestinal inflammation. Humanised anti-TNF-α antibodies have been shown to be effective in the treatment of active Crohn's disease and in the treatment of e...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of the rheumatic diseases

دوره 58 Suppl 1  شماره 

صفحات  -

تاریخ انتشار 1999